Skip to main content
KTTA
NASDAQ Life Sciences

FDA Grants Rare Pediatric Disease Designation to PAS-004, Opening Door to Potential $150M+ Priority Review Voucher

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$0.85
Mkt Cap
$18.515M
52W Low
$0.281
52W High
$3.79
52W Position info
202% above low
Off High info
78% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

KTTA has more than doubled off its 52-week low of $0.281.

Summary

Pasithea Therapeutics announced that the FDA has granted Rare Pediatric Disease Designation (RPDD) to its drug candidate, PAS-004, for the treatment of Neurofibromatosis Type 1 (NF1). This designation is highly significant as it makes the company eligible to receive a Priority Review Voucher (PRV) upon eventual New Drug Application (NDA) approval. Historically, PRVs have sold for $150-$205 million, representing a potential value many times the company's current market capitalization. This substantially de-risks the development pathway and provides a significant potential non-dilutive funding source. Investors will now closely watch the progress of PAS-004 through its ongoing Phase 1/1b clinical trials, as this designation is a major positive catalyst for the micro-cap biotech.

At the time of this announcement, KTTA was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.5M. The 52-week trading range was $0.28 to $3.79. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

KTTA - Latest Insights

KTTA
Nov 03, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.3591
Real-time Price: $0.5383 info
Change: +$0.1792 (+50%) info
Market Cap: $17.776M info
KTTA
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.550
Real-time Price: $0.5383 info
Change: -$0.0117 (-2%) info
Market Cap: $17.776M info
KTTA
Sep 09, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.5697
Real-time Price: $0.5383 info
Change: -$0.0314 (-6%) info
Market Cap: $17.776M info
KTTA
Aug 21, 2026, 5:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.490
Real-time Price: $0.5383 info
Change: +$0.0483 (+10%) info
Market Cap: $17.776M info
KTTA
Jul 29, 2026, 5:15 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.4231
Real-time Price: $0.5383 info
Change: +$0.1152 (+27%) info
Market Cap: $17.776M info